Eight Capital analyst Graeme Kreindler downgraded Aphria Inc (APHA) to Hold on December 13 and set a price target of $7. The company’s shares closed yesterday at $5.60, close to its 52-week low of $3.75.
According to TipRanks.com, Kreindler is ranked #4705 out of 5108 analysts.
Aphria Inc has an analyst consensus of Moderate Buy, with a price target consensus of $14.50.
See today’s analyst top recommended stocks >>
Based on Aphria Inc’s latest earnings release for the quarter ending August 31, the company reported a quarterly net profit of $16.33 million. In comparison, last year the company had a net profit of $5.14 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aphria, Inc. engages in the production and supply of medical cannabis. Its products include cannabis capsules, oral solutions, concentrate syringes and tetrahydrocannabinol and cannabidiol vaporizers. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.
Read More on APHA:
